Lung-derived soluble factors support stemness/plasticity and metastatic behaviour of breast cancer cells via the FGF2-DACH1 axis.
Breast cancer
Dachshund homolog 1 (DACH1)
Fibroblast growth factor 2 (FGF2)
Lung metastasis
Lung microenvironment
Stemness/plasticity
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
06 Apr 2024
06 Apr 2024
Historique:
received:
14
10
2023
accepted:
20
03
2024
medline:
6
4
2024
pubmed:
6
4
2024
entrez:
6
4
2024
Statut:
aheadofprint
Résumé
Patients with triple-negative breast cancer (TNBC) have an increased propensity to develop lung metastasis. Our previous studies demonstrated that stem-like ALDH
Identifiants
pubmed: 38581619
doi: 10.1007/s10585-024-10284-4
pii: 10.1007/s10585-024-10284-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : London Regional Cancer Program Catalyst Grant
ID : LHR F8319
Organisme : U.S. Army Department of Defense Breast Cancer Program
ID : BC160912
Informations de copyright
© 2024. The Author(s).
Références
Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G (2021) Breast cancer. Lancet 397(10286):1750–1769. https://doi.org/10.1016/s0140-6736(20)32381-3
doi: 10.1016/s0140-6736(20)32381-3
pubmed: 33812473
Momenimovahed Z, Salehiniya H (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 11:151–164. https://doi.org/10.2147/bctt.S176070
doi: 10.2147/bctt.S176070
pubmed: 31040712
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093
doi: 10.1038/35021093
pubmed: 10963602
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271–3277. https://doi.org/10.1200/jco.2009.25.9820
doi: 10.1200/jco.2009.25.9820
pubmed: 20498394
Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncol (Williston Park) 22(11):1233–1239 discussion 9–40, 43
Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC (2019) Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother 114:108800. https://doi.org/10.1016/j.biopha.2019.108800
doi: 10.1016/j.biopha.2019.108800
pubmed: 30921705
Rabbani SA, Mazar AP (2007) Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev 26(3–4):663–674. https://doi.org/10.1007/s10555-007-9085-8
doi: 10.1007/s10555-007-9085-8
pubmed: 17823779
Seyfried TN, Huysentruyt LC (2013) On the origin of cancer metastasis. Crit Rev Oncog 18(1–2):43–73. https://doi.org/10.1615/critrevoncog.v18.i1-2.40
doi: 10.1615/critrevoncog.v18.i1-2.40
pubmed: 23237552
pmcid: 3597235
Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF et al (1998) Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153(3):865–873. https://doi.org/10.1016/s0002-9440(10)65628-3
doi: 10.1016/s0002-9440(10)65628-3
pubmed: 9736035
pmcid: 1853000
Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101
pubmed: 2673568
Rashid OM, Takabe K (2012) The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis 4(4):420–424. https://doi.org/10.3978/j.issn.2072-1439.2012.07.16
doi: 10.3978/j.issn.2072-1439.2012.07.16
pubmed: 22934145
pmcid: 3426738
Xiao W, Zheng S, Liu P, Zou Y, Xie X, Yu P et al (2018) Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population-based study. Cancer Med 7(3):922–930. https://doi.org/10.1002/cam4.1370
doi: 10.1002/cam4.1370
pubmed: 29473333
pmcid: 5852337
Medeiros B, Allan AL (2019) Molecular mechanisms of breast Cancer metastasis to the lung: clinical and experimental perspectives. Int J Mol Sci 20(9). https://doi.org/10.3390/ijms20092272
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. https://doi.org/10.1016/j.stem.2007.08.014
doi: 10.1016/j.stem.2007.08.014
pubmed: 18371393
pmcid: 2423808
Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA et al (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13(8b):2236–2252. https://doi.org/10.1111/j.1582-4934.2008.00455.x
doi: 10.1111/j.1582-4934.2008.00455.x
pubmed: 18681906
Chu JE, Xia Y, Chin-Yee B, Goodale D, Croker AK, Allan AL (2014) Lung-derived factors mediate breast cancer cell migration through CD44 receptor-ligand interactions in a novel ex vivo system for analysis of organ-specific soluble proteins. Neoplasia (New York NY) 16(2):180–191. https://doi.org/10.1593/neo.132076
doi: 10.1593/neo.132076
Medeiros B, Goodale D, Postenka C, Lowes LE, Kiser P, Hearn S et al (2020) Triple-negative primary breast tumors induce supportive premetastatic changes in the Extracellular Matrix and Soluble Components of the lung microenvironment. Cancers 12(1). https://doi.org/10.3390/cancers12010172
Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J et al (2010) Modeling metastasis biology and therapy in real time in the mouse lung. J Clin Investig 120(8):2979–2988. https://doi.org/10.1172/jci40252
doi: 10.1172/jci40252
pubmed: 20644255
pmcid: 2912183
Khan SU, Xia Y, Goodale D, Schoettle G, Allan AL (2021) Lung-derived selectins enhance metastatic behavior of Triple negative breast Cancer cells. Biomedicines 9(11). https://doi.org/10.3390/biomedicines9111580
Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL et al (2011) Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin cancer Research: Official J Am Association Cancer Res 17(19):6151–6162. https://doi.org/10.1158/1078-0432.Ccr-10-3298
doi: 10.1158/1078-0432.Ccr-10-3298
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B et al (2017) UALCAN: a portal for facilitating Tumor Subgroup Gene expression and survival analyses. Neoplasia (New York NY) 19(8):649–658. https://doi.org/10.1016/j.neo.2017.05.002
doi: 10.1016/j.neo.2017.05.002
Győrffy B (2021) Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J 19:4101–4109. https://doi.org/10.1016/j.csbj.2021.07.014
doi: 10.1016/j.csbj.2021.07.014
pubmed: 34527184
pmcid: 8339292
Aman S, Li Y, Cheng Y, Yang Y, Lv L, Li B et al (2021) DACH1 inhibits breast cancer cell invasion and metastasis by down-regulating the transcription of matrix metalloproteinase 9. Cell Death Discov 7(1):351. https://doi.org/10.1038/s41420-021-00733-4
doi: 10.1038/s41420-021-00733-4
pubmed: 34772908
pmcid: 8590022
Zhao F, Wang M, Li S, Bai X, Bi H, Liu Y et al (2015) DACH1 inhibits SNAI1-mediated epithelial-mesenchymal transition and represses breast carcinoma metastasis. Oncogenesis 4(3):e143. https://doi.org/10.1038/oncsis.2015.3
doi: 10.1038/oncsis.2015.3
pubmed: 25775416
pmcid: 5399170
Xu H, Yu S, Yuan X, Xiong J, Kuang D, Pestell RG et al (2017) DACH1 suppresses breast cancer as a negative regulator of CD44. Sci Rep 7(1):4361. https://doi.org/10.1038/s41598-017-04709-2
doi: 10.1038/s41598-017-04709-2
pubmed: 28659634
pmcid: 5489534
Watanabe A, Ogiwara H, Ehata S, Mukasa A, Ishikawa S, Maeda D et al (2011) Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proc Natl Acad Sci USA 108(30):12384–12389. https://doi.org/10.1073/pnas.0906930108
doi: 10.1073/pnas.0906930108
pubmed: 21750150
pmcid: 3145721
Horner A, Shum L, Ayres JA, Nonaka K, Nuckolls GH (2002) Fibroblast growth factor signaling regulates Dach1 expression during skeletal development. Dev Dyn 225(1):35–45. https://doi.org/10.1002/dvdy.10132
doi: 10.1002/dvdy.10132
pubmed: 12203718
Mossahebi-Mohammadi M, Quan M, Zhang JS, Li X (2020) FGF signaling pathway: a Key Regulator of Stem Cell Pluripotency. Front Cell Dev Biol 8:79. https://doi.org/10.3389/fcell.2020.00079
doi: 10.3389/fcell.2020.00079
pubmed: 32133359
pmcid: 7040165
Chen S, Yang J, Liu Y, You H, Dong Y, Lyu J (2019) Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases. PeerJ 7:e8298. https://doi.org/10.7717/peerj.8298
doi: 10.7717/peerj.8298
pubmed: 31871847
pmcid: 6924336
Baumann Z, Auf der Maur P, Bentires-Alj M (2022) Feed-forward loops between metastatic cancer cells and their microenvironment-the stage of escalation. EMBO Mol Med 14(6):e14283. https://doi.org/10.15252/emmm.202114283
doi: 10.15252/emmm.202114283
pubmed: 35506376
pmcid: 9174884
Izraely S, Witz IP (2021) Site-specific metastasis: a cooperation between cancer cells and the metastatic microenvironment. Int J Cancer 148(6):1308–1322. https://doi.org/10.1002/ijc.33247
doi: 10.1002/ijc.33247
pubmed: 32761606
Vasilaki D, Bakopoulou A, Tsouknidas A, Johnstone E, Michalakis K (2021) Biophysical interactions between components of the tumor microenvironment promote metastasis. Biophys Rev 13(3):339–357. https://doi.org/10.1007/s12551-021-00811-y
doi: 10.1007/s12551-021-00811-y
pubmed: 34168685
pmcid: 8214652
Oskarsson T, Batlle E, Massagué J (2014) Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 14(3):306–321. https://doi.org/10.1016/j.stem.2014.02.002
doi: 10.1016/j.stem.2014.02.002
pubmed: 24607405
pmcid: 3998185
Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309–322. https://doi.org/10.1016/j.ccr.2012.02.022
doi: 10.1016/j.ccr.2012.02.022
pubmed: 22439926
Pein M, Insua-Rodríguez J, Hongu T, Riedel A, Meier J, Wiedmann L et al (2020) Metastasis-initiating cells induce and exploit a fibroblast niche to fuel malignant colonization of the lungs. Nat Commun 11(1):1494. https://doi.org/10.1038/s41467-020-15188-x
doi: 10.1038/s41467-020-15188-x
pubmed: 32198421
pmcid: 7083860
Smigiel JM, Taylor SE, Bryson BL, Tamagno I, Polak K, Jackson MW (2019) Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. J Cancer Metastasis Treat 5. https://doi.org/10.20517/2394-4722.2019.26
Lüönd F, Tiede S, Christofori G (2021) Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer 125(2):164–175. https://doi.org/10.1038/s41416-021-01328-7
doi: 10.1038/s41416-021-01328-7
pubmed: 33824479
pmcid: 8292450
Castiglioni V, Faedo A, Onorati M, Bocchi VD, Li Z, Iennaco R et al (2019) Dynamic and cell-specific DACH1 expression in human neocortical and Striatal Development. Cereb Cortex 29(5):2115–2124. https://doi.org/10.1093/cercor/bhy092
doi: 10.1093/cercor/bhy092
pubmed: 29688344
Chu Q, Han N, Yuan X, Nie X, Wu H, Chen Y et al (2014) DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. J Hematol Oncol 7:73. https://doi.org/10.1186/s13045-014-0073-5
doi: 10.1186/s13045-014-0073-5
pubmed: 25322986
pmcid: 4203876
Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y et al (2006) DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol 26(19):7116–7129. https://doi.org/10.1128/mcb.00268-06
doi: 10.1128/mcb.00268-06
pubmed: 16980615
pmcid: 1592900
Liu Q, Li A, Yu S, Qin S, Han N, Pestell RG et al (2018) DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis. J Hematol Oncol 11(1):53. https://doi.org/10.1186/s13045-018-0597-1
doi: 10.1186/s13045-018-0597-1
pubmed: 29636079
pmcid: 5894143
Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W et al (2011) Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem 286(3):2132–2142. https://doi.org/10.1074/jbc.M110.148395
doi: 10.1074/jbc.M110.148395
pubmed: 20937839
Haghighi F, Dahlmann J, Nakhaei-Rad S, Lang A, Kutschka I, Zenker M et al (2018) bFGF-mediated pluripotency maintenance in human induced pluripotent stem cells is associated with NRAS-MAPK signaling. Cell Commun Signal 16(1):96. https://doi.org/10.1186/s12964-018-0307-1
doi: 10.1186/s12964-018-0307-1
pubmed: 30518391
pmcid: 6282345
Levenstein ME, Ludwig TE, Xu RH, Llanas RA, VanDenHeuvel-Kramer K, Manning D et al (2006) Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells 24(3):568–574. https://doi.org/10.1634/stemcells.2005-0247
doi: 10.1634/stemcells.2005-0247
pubmed: 16282444
Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN (2011) FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell 43(2):285–298. https://doi.org/10.1016/j.molcel.2011.06.020
doi: 10.1016/j.molcel.2011.06.020
pubmed: 21777817
pmcid: 3324394
Raballo R, Rhee J, Lyn-Cook R, Leckman JF, Schwartz ML, Vaccarino FM (2000) Basic fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex. J Neurosci 20(13):5012–5023. https://doi.org/10.1523/jneurosci.20-13-05012.2000
doi: 10.1523/jneurosci.20-13-05012.2000
pubmed: 10864959
pmcid: 6772267
Jia T, Jacquet T, Dalonneau F, Coudert P, Vaganay E, Exbrayat-Héritier C et al (2021) FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC Biol 19(1):173. https://doi.org/10.1186/s12915-021-01103-3
doi: 10.1186/s12915-021-01103-3
pubmed: 34433435
pmcid: 8390225
Haley EM, Kim Y (2014) The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture. Cancer Lett 346(1):1–5. https://doi.org/10.1016/j.canlet.2013.12.003
doi: 10.1016/j.canlet.2013.12.003
pubmed: 24333730
Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R et al (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4(6):568–580. https://doi.org/10.1016/j.stem.2009.03.014
doi: 10.1016/j.stem.2009.03.014
pubmed: 19497285
Bado IL, Zhang W, Hu J, Xu Z, Wang H, Sarkar P et al (2021) The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells. Dev Cell 56(8):1100–17e9. https://doi.org/10.1016/j.devcel.2021.03.008
doi: 10.1016/j.devcel.2021.03.008
pubmed: 33878299
pmcid: 8062036
Popov VM, Zhou J, Shirley LA, Quong J, Yeow WS, Wright JA et al (2009) The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res 69(14):5752–5760. https://doi.org/10.1158/0008-5472.Can-08-3992
doi: 10.1158/0008-5472.Can-08-3992
pubmed: 19605405
pmcid: 3244171
Sundaram K, Mani SK, Kitatani K, Wu K, Pestell RG, Reddy SV (2008) DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells. J Cell Biochem 103(6):1747–1759. https://doi.org/10.1002/jcb.21561
doi: 10.1002/jcb.21561
pubmed: 17891780
pmcid: 2778848